<unk>  (INN) (former developmental code name DP-TAT-59) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was never marketed. It is a derivative of afimoxifene (4-hydroxytamoxifen) in which an additional 4-isopropyl group is present in the β-phenyl ring. The drug has been found to be 3- to 10-fold more potent than tamoxifen in inhibiting breast cancer cell growth in in vitro models.<unk>  is the active metabolite of<unk>  phosphate (TAT-59), a phosphate ester and prodrug of<unk>  that was developed to improve its water solubility.<unk>  phosphate was under development for the treatment of breast cancer and reached phase III clinical trials for this indication but development was discontinued.
Miproxifene
Telithromycin
Ciclopirox
Dirithromycin
Roxithromycin
Vilanterol
Diquafosol
Nifurtimox